Kornimate/medical-research-clean huggingface dataset:
virtual third-wave intervention for internalized weight bias combined with a weight loss program

Conditions: Weight Loss; Weight Prejudice

Summary: the current study aims to test a third-wave based iwb intervention paired with a standard bwlp delivered through video conferencing software.

internalized weight bias (iwb), has been shown to impact mental (e.g., depression and anxiety) and physical health (e.g., cardiometabolic functioning), as well as weight loss and weight loss associated behaviors (e.g., interference with exercise and healthy eating). these associated behaviors especially pose a risk for weight regain and disruption of healthy weight loss. therefore, given the association between iwb and weight loss associated behaviors, as well as the psychological and health risks associated with iwb, it is clear that iwb interventions are also needed independently and in conjunction with behavioral weight loss programs (bwlps). interventions using third-wave strategies (such as acceptance commitment therapy; act) have begun to show promise in reducing iwb, but have not yet looked at this therapy in conjunction with a bwlp. finally, there has also been a growing interest in and need for telehealth-based programs and interventions. the covid19 pandemic demonstrated a clear need for efficacious telehealth programs, and a further benefit is that these programs may reach populations with limited access to resources (i.e., rural populations). thus, the current study aims to examine a third-wave based iwb intervention paired with a standard bwlp delivered through video conferencing software.

Eligibility criteria:
inclusion: 1. interested in weight loss 2. 18 or older 3. bmi of 25 kg/m2 or greater 4. higher-than-average levels of iwb 5. access to internet, along with a web camera and sound, and be able to use video conferencing software and attend weekly online groups, and access to a reliable scale to weigh themselves weekly exclusion: 6. individuals with current use of medication prescribed for weight loss (such as orlistat, sibutramine, or rimonabant) 7. pregnant or planning to become pregnant

Keywords: behavioral weight loss program
establishing an inflammatory breast cancer registry

Conditions: Inflammatory Breast Cancer

Summary: inflammatory breast carcinoma (ibc) is an extremely rare, aggressive form of breast cancer that disproportionately impacts young women. ibc often affects the skin of the breast, as well as the breast itself, making it appear inflamed. the purpose of this study is to collect data and information on ibc patients so that researchers can study factors associated with ibc. the data and information collected will be used to establish the ibc registry, a private cancer registry. approximately 300 persons who are 18 years or older and who have been diagnosed with ibc will participate in this study. participants will provide researchers with access to their medical and pathology records, slides, tissue, and x-rays. they also will consent to a 15-minute telephone interview concerning general information about themselves and the initial manifestation of ibc and to a 30-minute interview about their medical history.

inflammatory breast carcinoma (ibc) is an extremely rare, aggressive form of breast carcinoma that disproportionately affects young women. clinical features of ibc include warmth, redness, edema, skin dimpling and rapid enlargement; the hallmark pathologically is dermal lymphatic invasion. minimal criteria necessary for a clinical diagnosis of ibc have been debated and relatively little is known about the epidemiology, pathogenesis and molecular characteristics of these very lethal tumors. this project, funded by a grant from the department of defense awarded to phl, would develop a national registry of approximately 300 volunteers (aged 18 years or older) with ibc. subjects will provide access to medical records, pathology records, slides, blocks and tissue (fixed and frozen) and x-rays and consent to an interview. recruitment will be performed at collaborating institutions and through an ibc research foundation (owen johnson) that maintains a website and e-mail contact lists. the registry resources would be made available collaboratively to anyone in the breast cancer research community, based on merit as determined by a designated committee. central aims of the study include determining whether clinically or pathologically defined ibc differs in clinical behavior or biologically, identifying markers in ibc that may provide useful information about the aggressive potential of breast cancers generally, and evaluation of tissue for mouse mammary tumor virus (mmtv) related sequences. the purpose of this irb submission is to review the role of mes as a collaborating pathologist on this study. enrollment is closed as of this time.

Eligibility criteria:
* patients will be recruited from collaborating institutions throughout the us and through the ibc research foundation (established by patient advocate, mr. owen johnson), which maintains a website and a research e-mail list. the goal is to recruit approximately 300 volunteers, at least 18 years of age or older.

Keywords: mammary diagnosis aggressive pathology epidemiology
behaviour and cognitive evaluation for dialysis elderly patients (bcde)

Conditions: Chronic Renal Insufficiency; Chronic Kidney Failure; Aged

Summary: the trial is a multicenter, prospective, randomized, open study. a total of 500 elderly patients aged over 75 years with renal insufficiency stage 5 will be included in the study after signed informed consent. patients will be randomized 1/1 in two arms : 250 patients in the "exclusive nephrology follow-up" arm will continue their usual follow-up; 250 patients in the "geriatric follow-up" arm will have both their usual nephrology follow-up and a geriatric follow-up. the aim of the study is to determine if a systematized gerontologist evaluation delay the occurrence of a composite primary endpoint : death, dementia, depression and severe dependency. the hypothesis is that the functional and vital prognosis of a patient with renal insufficiency depends not only on common and classical factors but also on cognitive and psychological functions and dependence, particularly in elderly patients.


Eligibility criteria:
inclusion criteria : * patients aged of 75 years old or more, * chronic kidney disease stage 5 defined by : * either an estimated gfr (mdrd) ≤ 15ml/mn/1,73 m² in a non-dialysis patient with a nephrology follow-up \> 3 months ("pre-dialysis cohort"), * or a dialysis treatment started for more than 3 months and less than one year, after a pre-dialysis follow-up \> 3 months ("post-dialysis cohort"), * signed and dated informed consent. exclusion criteria : * moderately severe to severe dementia (mms ≤ 15), * major depression and/or gds-15 \> 10/15, * severe dependency (adl \< 3/6)., * psychosis, mutism or aphasia, * malignancy or any pathology with life expectancy \< one year. * ongoing specialized geriatric care

Keywords: elderly patients renal insufficiency systematized gerontologic evaluation
clinical significance of marginal acute inflammation for stage ii colon cancer

Conditions: Inflammation; Colon Cancer

Summary: marginal acute inflammation would make reporting the serosal involvement of tumors controversial. we aimed to investigate the clinical significance and explore the prognostic value of mai for stage ii localized colon cancer.


Eligibility criteria:
inclusion criteria: * (1) colon cancer patients with the preoperative staging of stage i-iii who lacked distant metastasis; (2) patients who underwent radical resection, with postoperative pathology confirmed as pt3-4n0m0; and (3) complete follow-up information exclusion criteria: * (1) patients who received neo-adjuvant therapy; (2) patients with multiple primary colorectal cancer; and (3) patients with a history of malignant tumors
impact of preoperative oral branched-chain amino acids on reducing postoperative insulin resistance.

Conditions: Insulin Resistance; Colorectal Cancer

Summary: postoperative insulin resistance refers to the phenomenon that the body's glucose uptake stimulated by insulin is reduced due to stress effects such as trauma or the inhibitory effect of insulin on liver glucose output is weakened after surgery. there is a clear link between postoperative insulin resistance and poor perioperative prognosis. therefore, exploring interventions to reduce postoperative stress insulin resistance, stabilize postoperative blood glucose, and reduce postoperative complications are clinical problems that need to be solved urgently. in recent years, research on branched-chain amino acids and metabolic diseases has become a hot spot. studies have found that in the rat model, preoperatively given a high branched-chain amino acid diet can inhibit postoperative insulin resistance and stabilize blood glucose levels. this research plan is to try to add branched-chain amino acids before surgery to observe the occurrence of postoperative insulin resistance in patients.


Eligibility criteria:
inclusion criteria: 1. age 50-80 years old ; 2. clinical diagnosis of colorectal cancer; 3. planned elective laparoscopic radical resection of colorectal cancer; 4. preoperative american society of anesthesiologists（asa）score grade i-iii ; 5. informed consent was obtained from patients. exclusion criteria: 1. clinical diagnosis of diabetes mellitus; 2. preoperative insulin resistance ; 3. renal insufficiency requires dialysis, hepatic insufficiency (child - pugh grade b and above); 4. eating disorders caused by gastrointestinal obstruction; 5. pregnant or lactating women; 6. patients with severe mental illness.

Keywords: postoperative insulin resistance branched chain amino acids colorectal cancer
evaluation of dentists burnout in turkey

Conditions: Burnout, Psychological

Summary: the aim of this study is to determine the level of burnout in turkish dentists. the copenhagen burnout inventory of 19 questions will be used to assess burnout; and 4 more about; gender, occupational age, institution and title. all surveys will be conducted online and we plan to reach approximately 400 participants. after the burnout levels are determined, it will be statistically investigated whether there is a difference between the groups according to gender, occupational age, institution and title.


Eligibility criteria:
inclusion criteria: * being a dentist who is still working * accepted electronically to participate in our study * completed and submitted our electronic questionnaires successfully exclusion criteria: * did not answer all questions of survey
shr9549 in er positive her2 negative advanced breast cancer

Conditions: ER+ HER2- Advanced Breast Cancer

Summary: this is a phase 1 open label multicentre study of shr9549 administered orally in patients with advanced estrogen receptor (er) positive human epidermal receptor 2 (her2) negative breast cancer. the study design allows an escalation of dose with intensive safety monitoring to ensure the safety of patients. the study will determine the maximum tolerated dose(mtd). in addition, expansion cohort(s) at potential therapeutic dose(s) in patients will be enrolled to further determine the safety, tolerability, pharmacokinetics and biological activity of shr9549.

a phase i, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of ascending doses of shr9549 in women with estrogen receptor (er) positive human epidermal receptor (her-2) negative advanced breast cancer

Eligibility criteria:
inclusion criteria: * aged 18-70 years. * confirmation of er positive; her2 negative advanced breast cancer * documented disease progression after at least 6 months prior endocrine therapy for er positive breast cancer. * receipt of ≤2 lines of prior chemotherapy for advanced disease. * any menopausal status. * eastern cooperative oncology group (ecog) performance status 0-1 and with minimum life expectancy of 12 weeks. exclusion criteria: * any anti-cancer drugs for the treatment of advanced breast cancer within 14 days of the first dose of study treatment. * any unresolved toxicities from prior therapy greater than ctcae grade 1 at the time of starting study treatment with the exception of alopecia. * patient who is unsuitable for endocrine therapy alone including presence of life-threatening metastatic visceral disease. * uncontrolled central nervous system metastatic disease. * any evidence of severe or uncontrolled systemic diseases. * inadequate bone marrow reserve or organ function.
the effects of game based exercise training on balance and postural control in patients with ataxia

Conditions: Ataxia

Summary: this study was planned to investigate the effects of exercise training based on microsoft kinect application on balance and postural control in ataxic patients.

patients who meet the inclusion criteria will be divided into two groups randomly: 'kinect and exercise training' and 'exercise training'. the assessments will be made by a blind investigator four times, before and after the implementation of both protocols. the evaluations will take approximately 1 hour. the demographic information of the cases will be recorded. designed as cross over study, two treatment protocols will be used in this study. the first protocol will be xbox kinect application plus exercise program, the second protocol will be only exercise program. at the beginning of the study, 2 groups will be allocated (group a and group b) randomly. for group a, the xbox kinect application plus exercise program will be applied for the first 8 weeks. for group b, only exercise program will be applied therapy first 8 weeks. all assessments will be repeated before and after each therapy period. exercise program will consist of selected balance, coordination and walking exercises according to the individual needs of patients. after 10 weeks washout period, patients will be included in the other group. all patients will take the treatment 1-hour, 3 days in a week for 8 weeks.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of ataxia * ataxic patients who are able to walk 25 m independently * ataxic patients who had a mini mental test score of 24 points and over; exclusion criteria: * clinical diagnosis of systemic problems (diabetes mellitus, hypertension) * clinical diagnosis of cognitive impairment * patients who have fallen at least once in the last 6 months * patients who had berg balance scale score of 40 points and below
factors associated with hyponatremia induced by high-dose cyclophosphamide

Conditions: Hyponatremia

Summary: prospoctive cohort of high-dose cyclophosphamide exposed patients. with active estandardize screening of hyponatremia development in the follow up period.

primary objectives 1. to identify the factors associated with the development of hyponatremia in patients receiving high-dose cyclophosphamide (2.5 grams or more). 2. generate and validate a predictive score of developing hyponatremia high-dose cyclophosphamide. 3. to estimate the incidence of hyponatremia in patients undergoing high-dose cyclophosphamide. study design. observational prospective cohort study of patients after infusion of high-dose cyclophosphamide. follow up period will be from cyclophosphamide infusion until one month after hospital discharge.

Eligibility criteria:
inclusion criteria: * adult patients (over 18 years) who were admitted to the hematology / oncology and medical clinic hospital italiano de buenos aires infusion of high-dose cyclophosphamide for conducting msch prior bmt, gatla and hypercvad in the period 2015-2017. exclusion criteria: * refusal to participate or to the process of informed consent.

Keywords: drug induced hyponatremia cyclophosphamide hyponatremia cyclophosphamide induced hyponatremia
a study to evaluate safety, tolerability, and pharmacokinetics of sage-718 oral solution in patients with huntington's disease - part b

Conditions: Huntington Disease

Summary: this study is a phase 1, double-blind, placebo-controlled, multiple ascending dose study to determine the safety, tolerability, and pharmacokinetics of sage-718 oral solution in healthy adults (part a) with an open-label cohort of patients with huntington's disease (part b)

this posting addresses part b

Eligibility criteria:
inclusion criteria: 1. subject is positive for mutant htt (documented cag repeats ≥ 40 units). 2. subject has a body weight ≥50 kg and body mass index ≥18.0 and ≤30.0 kg/m2 at screening. exclusion criteria: 1. subject has any clinically significant abnormal finding on the physical exam at screening or admission. 2. subject has a history or presence of a neurologic disease or condition (other than huntington's disease), including but not limited to severe chorea, epilepsy, closed head trauma with clinically significant sequelae, or a prior seizure. 3. subject has a family history of epilepsy. 4. subject has a positive screening test for alcohol or drugs of abuse (including marijuana) at screening or admission.
comparison of lumbar muscle thickness measurements in osteoporotic and osteopenic patients

Conditions: Osteoporosis

Summary: in osteoporosis, sarcopenia is a common condition. sarcopenic measurements can be made by evaluating muscle thickness in different regions. we aim to evaluate lumbar muscle losses in patients with osteoporosis in the lumbar region and to examine whether these muscle losses are correlated with the level of osteoporosis. the patients will be divided into 3 groups as healthy, osteopenic and osteoporotic according to dexa measurements. demographic values, comorbidities, osteoporosis drugs used, fracture histories, l1-4, l2-4, femoral neck and total bmd and t values of the patients, psoas and multifidus muscle measurements will be made at l2-l3 level in lumbar mr imaging. lumbar mr muscle measurements will be made by 1 physician blind to the dexa values of the patients.


Eligibility criteria:
inclusion criteria: * 50-90 years old * 2. recent mri of the lumbar region with dexa evaluation exclusion criteria: * have had previous lumbar surgery * any previous lumbar injection * stage 3-4 lumbar listesis * presence of lumbar discopathy accompanied by neurological deficit
minimizing glucocorticoid administration in patients with proliferative lupus nephritis

Conditions: Lupus Nephritis

Summary: the aim of the study is to evaluate the efficacy of a therapeutic regimen which decreases glucocorticoid exposure compared with standard therapy in patients with proliferative lupus nephritis during remission induction by evaluating the histological and clinical remission.

after an initial screening phase during which a first kidney biopsy is performed, all patients that meet the inclusion criteria will be randomized to one of the treatment arms: * eurolupus regimen: 3 daily pulses of 750 mg of intravenous methylprednisolone, followed by oral corticosteroid therapy starting with a dose of 0.5 mg / kg / day for 4 weeks, then decreased by 2.5 mg of prednisolone / day each 2 weeks. a low dose of glucocorticoid (5-7.5 mg / day) is maintained until 24 months after enrollment. all patients will receive cyclophosphamide intravenously starting day 1, 6 pulses at a fixed dose of 500 mg given at 2 weeks. after 3 months, azathioprine (2 mg / kg / day) is initiated 2 weeks after the last administration of cyclophosphamide and maintained for the next 21 months. * rituxilup regimen: 2 doses of rituximab 1 g and methylprednisolone 500 mg on days 1 and 15. patients will receive mycophenolate mofetil, initially 500 mg twice daily, titrated to a maximum of 1.5 g twice daily, depending on leukocyte count and digestive tolerance, which will be maintained 24 months. second kidney biopsy will be performed 6 months after the start of the treatment phase.

Eligibility criteria:
inclusion criteria: * age of the patient between 18 and 80 years, * patients diagnosed with systemic lupus erythematosus according to acr 1997 or slicc-2012 criteria * diagnosis of proliferative lupus nephritis class iii, iv +/- v (confirmed by renal biopsy and classified according to isn / rps); * estimated glomerular filtration rate by ckd-epi\> 30 ml / min / 1.73 sqm * estimated glomerular filtration rate by ckd-epi \ 15 ml / min / 1.73 sqm with chronicity index (according to nih score) \<6 * absence of contraindications to the use of methylprednisolone, mycophenolate mofetil, oral corticosteroids or rituximab * ability to provide informed consent exclusion criteria: * the patient's age under 18 years * patients with life-threatening complications (e.g. cerebritis) * estimated glomerular filtration rate by ckd-epi \<30 ml / min / 1.73 sqm * estimated glomerular filtration rate by ckd-epi \ 15 ml / min / 1.73 sqm with chronicity index (according to nih score)\> 6 * presence of pregnancy / lactation * patients who have received more than 2 g of methylprednisolone intravenously in the last 4 weeks * use in the last 3 months of biological therapy * use of intravenous immunoglobulins / plasmapheresis in the last 6 months * the presence of an active infection * history of neoplasia * comorbidities requiring systemic corticosteroid therapy * non-adhesion

Keywords: immunosuppression glucocorticoids eurolupus rituxilup induction therapy
virtual action planning in stroke: a control rehabilitation study

Conditions: Stroke

Summary: * background : the general experience with the virtual reality application approach suggests that this treatment concept is promising in stroke rehabilitation * purpose : in shopping activity in a real supermarket and in simulated with the investigators virtual shopping simulation (vap-s = virtual action planning supermarket), the investigators will compare people who had undergone a stroke who receive conventional rehabilitation or virtual training in vap-s.

the objective of this study is firstly to examine the effectiveness of using virtual reality-based training vap-s on the ability to run errands in a real supermarket in individuals with stroke. virtual environment provide useful way to explore planning and secondly to examine the effectiveness of using vr in the assessment of cognitive planning for patients. a virtual supermarket was designed in which participants carried out a task close to daily activities: a test of shopping list. of the 70 subjects (7 centres), 35 randomly allocated to the control group, and the other 35 subjects randomly allocated to the experimental group. subjects will be evaluated by a therapist who will not be involved in the training program and did not know about the subject's group assignment. statistical analysis : we will calculate descriptive statistics for the clinical characteristics of each group. we will use to compare the baseline demographic characteristics, the pretraining and posttraining variables between groups, independent-samples t-tests for means and chi-square tests for frequencies. a significance level of 0.05 is set for all analyses.

Eligibility criteria:
inclusion criteria: * adults * 1 to 18 months after stroke * without dementia or previous clinical stroke * with executive impairment (grefex battery) * barthel score equal or more than 40 * with cognitive disability leading to specific rehabilitation * given and informed consent exclusion criteria: * dementia or severe psychiatric disease * epilepsy * disorder of consciousness * visual agnosia * severe visual impairment